Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Perez Plasencia, Carlos ^a   Duenas Gonzalez, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; TRANSCRIPTOME; VALPROIC ACID;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CELL PROLIFERATION; CHROMATIN; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CARCINOMA; DEACETYLATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENOME; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MAMMAL CELL; NONHUMAN; PHENOTYPE; PROGNOSIS; PROTEIN MODIFICATION;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; METHYLATION; MODELS, THEORETICAL; NEOPLASMS;

MAMMALIA;

EID: 33747341830     PISSN: 14764598     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-27     Document Type: Article

References (40)

1. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003, 22:188-199.
2. Townsend DM, Tew KD: The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
3. Mashima T, Tsuruo T: Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat 2005, 8:339-343.
4. Oza AM: Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 2002, 243:103-115.
5. Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005, 5:30.
6. Weinstein IB: Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 2000, 21:857-864.
7. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006, 6:107-116.
8. Yap Y, Zhang X, Ling MT, Wang X, Wong YC, Danchin A: Classification between normal and tumor tissues based on the pairwise gene expression ratio. BMC Cancer 2004, 4:72.
9. Warnat P, Eils R, Brors B: Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics 2005, 6:265.
10. Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foà R, Belardelli FM: The use of microarray technologies in clinical oncology. J Transl Med 2006, 4:8.
11. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, Couillault C, Lajemi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S: Deciphering cellular states of innate tumor drug responses. Genome Biol 2006, 7:R19.
12. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA: Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5:78.
13. Glasspool RM, Teodoridis JM, Brown R: Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006, 94:1087-1092.
14. Baker EK, El-Osta A: The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp Cell Res 2003, 290:177-194.
15. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999, 21:103-107.
16. Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP, Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 2003, 63:2164-2171.
17. Li L, Shi H, Yiannoutsos C, Huang TH, Nephew KP: Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol 2005, 12:370-390.
18. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006, 6:2.
19. Hsiao HL, Wang WS, Chen PM, Su Y: Overexpression of thymosin {beta}-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis 2006, 27:936-944.
20. Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B: Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmacol 2002, 49:445-452.
21. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL: Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999, 5:2908-2917.
22. Feinberg AP, Cui H, Ohlsson R: DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 2002, 12:389-398.
23. Dunn BK: Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003, 983:28-42.
24. Fruhwald MC, Plass C: Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab 2002, 75:1-16.
25. Neumeister P, Albanese C, Balent B, Greally J, Pestell RG: Senescence and epigenetic dysregulation in cancer. Int J Biochem Cell Biol 2002, 34:1475-1490.
26. Tycko B: Genetic and epigenetic mosaicism in cancer precursor tissues. Ann N Y Acad Sci 2003, 983:43-54.
27. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L, Dopazo J: BABELOMICS: a suite of web tools for functional annotation and analysis of groups of genes in high-throughput experiments. Nucleic Acids Res 2005, 33:W460-464.
28. Babelomics, the systems biology way to functional annotation of genome-scale experiments [http://fatigo.bioinfo.cipf.es/]
29. Teodoridis JM, Strathdee G, Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004, 7:267-278.
30. Baker EK, Johnstone RW, Zalcberg JR. El-Osta A: Epigenetic changes to the MDRI locus in response to chemotherapeutic drugs. Oncogene 2005, 24:8061-8075.
31. Tian K, Jurukovski V, Wang XP, Kaplan MH, Xu H: Epigenetic regulation of WTH3 in primary and cultured drug-resistant breast cancer cells. Cancer Res 2005, 65:10024-10031.
32. Nyce JW: Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. Mutat Res 1997, 386:153-161.
33. Nyce J, Leonard S, Canupp D, Schulz S, Wong S: Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc Natl Acad Sci USA 1993, 90:2960-2964.
34. Nyce J: Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 1989, 49:5829-5836.
35. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R: Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLHI gene promoter. Cancer Res 2000, 60:6039-6044.
36. Qiu YY, Mirkin BL, Dwivedi RS: Inhibition of DNA methyltransferase reverses cisplatin induced drug resistance in murine neuroblastoma cells. Cancer Detect Prev 2005, 29:456-463.
37. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anti-cancer drugs targeting DNA. Cancer Res 2003, 63:7291-7300.
38. Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, Bader P, Beck JF: Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma. cells. Int J Oncol 2006, 28:755-766.
39. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006, 5:37-50.
40. Cernilogar FM, Orlando V: Epigenome programming by Polycomb and Trithorax proteins. Biochem Cell Biol 2005, 83:322-331.